MRC Technology Appoints Finance Director
News Apr 17, 2015
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014. He brings a wealth of senior international finance experience from previous roles at leading technology and pharmaceutical companies, including Syniverse Technologies, Astellas Pharma and Merck Serono.
Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Andrew has been a great asset to the Executive Team and the business since he joined last summer. MRC Technology is increasing its global partnerships, and Andrew’s EMEA, Asia and USA experience is a valued contribution to our drive to improve health through science across the world.”
Andrew Mercieca responded, saying: “MRC Technology has an impressive track record of connecting promising research with industry to ensure it fulfils its potential and making treatments available to patients, and I am very pleased to be supporting these efforts.”
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE